857636-97-6

Basic information

• Product Name: 2-(3-hydroxypiperidin-1-yl)acetonitrile
• Synonyms: 2-(3-hydroxypiperidin-1-yl)acetonitrile
• CAS NO: 857636-97-6
• Molecular Formula: C7H12N2O
• Molecular Weight: 140.19
• Mol File: 857636-97-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-hydroxypiperidin-1-yl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-hydroxypiperidin-1-yl)acetonitrile(857636-97-6)
• EPA Substance Registry System: 2-(3-hydroxypiperidin-1-yl)acetonitrile(857636-97-6)

Safety Data

• Hazardous Substances Data: 857636-97-6(Hazardous Substances Data)

Usage

Derivative of piperidine

Heterocyclic amine

Piperidine ring

Contains a hydroxy group attached to the third carbon

Nitrile group

Attached to the acetonitrile moiety

Usage

Organic synthesis as a building block for pharmaceutical and agrochemical compounds

Potential applications

Medicinal chemistry as a ligand for biological targets

Additional use

Chemical intermediate in the production of other organic compounds

Upstream product

• 6859-99-0 3-hydroxypiperazine 
• 590-17-0 cyanomethyl bromide 

Downstream Products

• 847499-95-0 1-(2-aminoethyl)piperidin-3-ol 

Relevant articles and documents

SMALL MOLECULES INHIBITING TDP-43 ACTIVITY AND USES THEREOF

The present invention relates to the field of medical pharmacology. In particular, the present invention relates to pharmaceutical agents that serve as inhibitors of the activity of TDP-43. The invention further relates to methods of treatment and / or alleviation of symptoms related to pathological conditions associated with the activity of TDP-43 (for example, neurodevelopmental disorders), comprising the administration to a subject (for example, a human patient) of a composition comprising one or more pharmaceutical agents serving as inhibitors of the activity of TDP-43.

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells

A novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780/cp70 and A2780/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice.